TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF

1 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is H, halo, C 1-6 alkyl, non-aromatic C 3-8 carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10-membered bicyclic heterocyclyl, phenyl, naphthyl, 5 or 6-membered monocyclic heteroaryl, or 9 or 10-membered bicyclic heteroaryl, wherein the C 1-6 alkyl is optionally substituted with one to three R 1a , wherein the non-aromatic C 3-8 carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10-membered bicyclic heterocyclyl, phenyl, naphthyl, 5 or 6-membered monocyclic heteroaryl, and 9 or 10-membered bicyclic heteroaryl are each optionally substituted with one to three R 1c ;

R 1a , for each occurrence, is independently halo, —OR 1b , non-aromatic C 3-8 carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10-membered bicyclic heterocyclyl, phenyl, naphthyl, 5 or 6-membered monocyclic heteroaryl, or 9 or 10-membered bicyclic heteroaryl, wherein the non-aromatic C 3-8 carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10-membered bicyclic heterocyclyl, phenyl, naphthyl, 5 or 6-membered monocyclic heteroaryl, and 9 or 10-membered bicyclic heteroaryl are each optionally substituted with one to three R 1c ;

R 1b is H, C 1-6 alkyl, or —[CH 2 —CH 2 —O] z —CH 3 ;

z is 1 to 3;

R 1c , for each occurrence, is independently halo, C 1-6 alkyl, C 1-6 haloalkyl, —OR 1b , —NR 1d R 1d , —CN, —NO 2 , —C(O)R 1b , —C(O)OR 1b , —C(O)NR 1d R 1d , or —NR 1d C(O)R 1b ;

R 1d is H or C 1-6 alkyl;

R 2 is H or C 1-6 alkyl;

or R 1 and R 2 , together with the carbon to which they are attached, form a non-aromatic C 3-8 carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10-membered bicyclic heterocyclyl, phenyl, naphthyl, 5 or 6-membered monocyclic heteroaryl, or 9 or 10-membered bicyclic heteroaryl, each of which is optionally substituted with one to three R 1c ;

R 3 is H, halo, C 1-6 alkyl, non-aromatic C 3-8 carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10-membered bicyclic heterocyclyl, phenyl, naphthyl, 5 or 6-membered monocyclic heteroaryl, or 9 or 10-membered bicyclic heteroaryl, wherein the C 1-6 alkyl is optionally substituted with one to three R 3a , wherein the non-aromatic C 3-8 carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10-membered bicyclic heterocyclyl, phenyl, naphthyl, 5 or 6-membered monocyclic heteroaryl, and 9 or 10-membered bicyclic heteroaryl are each optionally substituted with one to three R 3c ;

R 3a , for each occurrence, is independently halo, —OR 3b , non-aromatic C 3-8 carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10-membered bicyclic heterocyclyl, phenyl, naphthyl, 5 or 6-membered monocyclic heteroaryl, or 9 or 10-membered bicyclic heteroaryl, wherein the non-aromatic C 3-8 carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10-membered bicyclic heterocyclyl, phenyl, naphthyl, 5 or 6-membered monocyclic heteroaryl, and 9 or 10-membered bicyclic heteroaryl are each optionally substituted with one to three R 3c ;

R 3b is H, C 1-6 alkyl, or —[CH 2 —CH 2 —O] y —CH 3 ;

y is 1 to 3;

R 3c , for each occurrence, is independently halo, C 1-6 alkyl, C 1-6 haloalkyl, —OR 3b , —NR 3d R 3d , —CN, —NO 2 , —C(O)R 3b , —C(O)OR 3b , —C(O)NR 3d R 3d , or —NR 3d C(O)R 3b ;

R 3d is H or C 1-6 alkyl;

R 4 is H or C 1-6 alkyl;

R 5 is H, halo, —NR 5a R 5b , C 1-6 alkyl, or C 1-6 haloalkyl;

R 5a and R 5b are each independently H or C 1-6 alkyl;

provided that the pharmaceutical composition does not comprise a compound of the formulas below:

or a pharmaceutically acceptable salt thereof.

2 . The pharmaceutical composition of claim 1 , wherein R 5 is —CH 3 .

3 . The pharmaceutical composition of claim 1 , wherein R 1 is:

(i) H, C 1-6 alkyl, non-aromatic C 3-8 carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, phenyl, or 5 or 6-membered monocyclic heteroaryl, wherein the C 1-6 alkyl is optionally substituted with one to three R 1a , wherein the non-aromatic C 3-8 carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, phenyl, or 5 or 6-membered monocyclic heteroaryl are each optionally substituted with one or two R 1c , or wherein R 1 and R 2 , together with the carbon to which they are attached, form phenyl optionally substituted with one or two R 1c ; or

(ii) non-aromatic C 3-8 carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, phenyl, or 5 or 6-membered monocyclic heteroaryl, wherein the non-aromatic C 3-8 carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, phenyl, or 5 or 6-membered monocyclic heteroaryl are each optionally substituted with one or two R 1c ; or

(iii) selected from the group consisting of bicyclo[1.1.1]pentanyl, phenyl, pyridyl, thiophenyl, tetrahydropyranyl, tetrahydrofuranyl, and oxetanyl, each of which is optionally substituted with one or two R 1c .

4 .- 6 . (canceled)

7 . The pharmaceutical composition of claim 2 , wherein R 1c , for each occurrence, is C 1-6 alkyl, —OR 1b , or halo, and wherein R 1b is —[CH 2 —CH 2 —O] z —CH 3 .

8 . The pharmaceutical composition of claim 1 , wherein R 3 is:

(i) H, C 1-6 alkyl, 6 to 10-membered bicyclic heterocyclyl, phenyl, or 5 or 6-membered monocyclic heteroaryl, wherein the C 1-6 alkyl is optionally substituted with one to three R 3a , wherein the 6 to 10-membered bicyclic heterocyclyl, phenyl, or 5 or 6-membered monocyclic heteroaryl are each optionally substituted with one to three R 3c ; or

(ii) phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thiophenyl, benzodioxoyl, furanyl, oxazoyl, oxadiazoyl, pyrazoyl, or triazoyl, wherein the phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thiophenyl, benzodioxoyl, furanyl, oxazoyl, oxadiazoyl, pyrazoyl, or triazoyl, are each optionally substituted with one to two R 3c .

9 .- 11 . (canceled)

12 . The pharmaceutical composition of claim 1 , wherein the compound is represented by Formula (II):

or a pharmaceutically acceptable salt thereof, wherein:

m is 0 to 2;

R 1c is independently halo, C 1-6 alkyl, or —OR 1b ;

R 1b is —[CH 2 —CH 2 —O] z —CH 3 ;

R 3 is 5 or 6-membered monocyclic heteroaryl optionally substituted with one or two R 3c ;

R 3c is halo or C 1-6 alkyl.

13 . The pharmaceutical composition of claim 12 , wherein R 3 is pyridyl.

14 . The pharmaceutical composition of claim 8 , wherein R 3c , for each occurrence, is;

(i) halo, C 1-6 alkyl, C 1-6 haloalkyl, —OR 3b , or —C(O)N 3d R 3d ; or

(ii) —CH 3 , —CF 3 , —Cl, —F, —OCH 3 , —OCH(CH 3 ) 2 , or —C(O)NH 2 .

15 . (canceled)

16 . The pharmaceutical composition of claim 13 , wherein R 2 and R 4 are both H.

17 . The pharmaceutical composition of claim 1 , wherein R 1a is —OR 1b , and R 3a , for each occurrence, is independently halo, —OR 3b , or 5 or 6-membered monocyclic heteroaryl.

18 . The pharmaceutical composition of claim 3 , wherein R 1c is —F, —Cl, or —CH 3 and R 3c is —F, Cl, or —CH 3 .

19 . The pharmaceutical composition of claim 1 , wherein the compound is selected from:

6-benzyl-2-methyl-N-((5-methylfuran-2-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-((5-fluoropyridin-2-yl)methyl)-2-methyl-N-((5-methylfuran-2-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-N-((5-methyloxazol-2-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-N-((2-methyloxazol-5-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-N-(3-methylbenzyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-N-((6-methylpyridin-2-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-N-((1-methyl-1H-1,2,3-triazol-4-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-N-((2-methyl-2H-1,2,3-triazol-4-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-N-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-2-methyl-5-oxo-6-((tetrahydrofuran-2-yl)methyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-5-oxo-N-(pyridin-4-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-N-((1-methyl-1H-pyrazol-3-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-N-((1-methyl-1H-pyrazol-4-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-N-(2-fluorobenzyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

N,6-dibenzyl-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-N-((2-methyloxazol-4-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-N-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-6-(2-methoxyethyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(2-methoxyethyl)-2-methyl-N-((2-methyloxazol-5-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-N-(4-chlorobenzyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-5-oxo-N-(pyridin-3-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-N-(4-methoxybenzyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-5-oxo-N-(4-(trifluoromethyl)benzyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-2-methyl-5-oxo-6-((tetrahydro-2H-pyran-2-yl)methyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-2-methyl-6-(oxetan-2-ylmethyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-5-oxo-N-(1-(pyridin-2-yl)ethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-5-oxo-N-(pyrimidin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(2-methoxyethyl)-2-methyl-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(4-chlorobenzyl)-2-methyl-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-5-oxo-N-(pyrazin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-5-oxo-N-(pyridazin-3-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-5-oxo-N-(pyrimidin-5-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-N-((5-fluoropyridin-2-yl)methyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-N-((3-fluoropyridin-2-yl)methyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

2-methyl-5-oxo-6-(1-phenylethyl)-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-N-((5-chloropyridin-2-yl)methyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-N-((4-fluoropyridin-2-yl)methyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(cyclohexylmethyl)-2-methyl-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

2-methyl-5-oxo-N,6-bis(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-N,2-dimethyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-N-(4-carbamoylbenzyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-((5-fluoropyridin-2-yl)methyl)-2-methyl-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-isopropyl-2-methyl-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

2-methyl-5-oxo-6-phenyl-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(4-fluorobenzyl)-2-methyl-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

2-methyl-6-((5-methyloxazol-2-yl)methyl)-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

2-methyl-6-((1-methyl-1H-pyrazol-4-yl)methyl)-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-N-((4,5-difluoropyridin-2-yl)methyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(4-chlorobenzyl)-N-((5-fluoropyridin-2-yl)methyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

2-methyl-5-oxo-N-(pyridin-2-ylmethyl)-6-(pyridin-4-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

2,6-dimethyl-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

2-methyl-6-(4-methylbenzyl)-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(3-fluorobenzyl)-2-methyl-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(2-fluorobenzyl)-2-methyl-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-N-((5-chloro-4-fluoropyridin-2-yl)methyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

2-methyl-5-oxo-N-(pyridin-2-ylmethyl)-6-(pyridin-3-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

N-((5-chloropyridin-2-yl)methyl)-6-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(bicyclo[1.1.1]pentan-1-ylmethyl)-2-methyl-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(3,4-difluorobenzyl)-2-methyl-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(3,4-difluorobenzyl)-N-((4,5-difluoropyridin-2-yl)methyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(3,4-difluorobenzyl)-N-((5-fluoropyridin-2-yl)methyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

N-((5-chloropyridin-2-yl)methyl)-6-(4-(2-(2-methoxyethoxy)ethoxy)benzyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-N-((4-methyloxazol-2-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-N-(4-isopropoxybenzyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-N-(4-methylbenzyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-ylmethyl)-6-benzyl-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

2-methyl-N-((5-methylfuran-2-yl)methyl)-5-oxo-6-(thiophen-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-2-methyl-5-oxo-N-(thiophen-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(2-methoxyethyl)-2-methyl-N-((5-methylfuran-2-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-benzyl-N-(2-(furan-2-yl)ethyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

2-amino-6-benzyl-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(4-chloro-3-fluorobenzyl)-2-methyl-5-oxo-N-(pyridin-2-ylmethyl)-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(4-chlorobenzyl)-N-((5-(2-(2-methoxyethoxy)ethoxy)pyridin-2-yl)methyl)-2-methyl-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(3,4-difluorobenzyl)-2-methyl-N-((2-methyloxazol-4-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(4-fluorobenzyl)-2-methyl-N-((2-methyloxazol-4-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(3-fluorobenzyl)-2-methyl-N-((2-methyloxazol-4-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

6-(4-chlorobenzyl)-2-methyl-N-((2-methyloxazol-4-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide; and

6-(3,5-difluorobenzyl)-2-methyl-N-((2-methyloxazol-4-yl)methyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carboxamide;

or a pharmaceutically acceptable salt thereof.

20 . A compound represented by Formula (II):

or a pharmaceutically acceptable salt thereof, wherein:

R 2 is H or C 1-6 alkyl;

R 4 is H or C 1-6 alkyl;

R 1c is independently halo or C 1-6 alkyl;

m is 0 to 2;

when m is 0, R 3 is a 5-membered monocyclic heteroaryl selected from the group consisting of oxazoyl, oxadiazoyl, pyrazoyl, and triazoyl or a 6-membered monocyclic heteroaryl, each of which is optionally substituted with one or two R 3c ; or

when m is 1 or 2, R 3 is 5 or 6-membered monocyclic heteroaryl optionally substituted with one or two R 3c ;

R 3c is halo or C 1-6 alkyl.

21 . The compound of claim 20 , or a pharmaceutically acceptable salt thereof, wherein R 2 and R 4 are both H.

22 . The compound of claim 20 , or a pharmaceutically acceptable salt thereof, wherein R 3 is pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, oxazoyl, oxadiazoyl, pyrazoyl, or triazoyl, each of which is optionally substituted with one to two R 3c .

23 . The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein R 3 is pyridyl.

24 . The compound of claim 20 , or a pharmaceutically acceptable salt thereof, wherein each R 1c is independently H, —Cl, —F, or —CH 3 , and wherein each R 3c is independently —F, —Cl, or —CH 3 .

25 . (canceled)

26 . A method of treating a disease mediated by Transcription factor EB, comprising administering to a subject an effective amount of a compound of claim 20 , or a pharmaceutically acceptable salt thereof.

27 . A method of treating a lysosomal storage disorder, infection, metabolic disease, muscle disease, neurodegenerative disease, renal disease, hematologic disease, or optical disease, comprising administering to a subject an effective amount of a compound of claim 20 , or a pharmaceutically acceptable salt thereof.

28 . (canceled)

29 . A method of treating a disease mediated by Transcription factor EB, comprising administering to a subject an effective amount of the pharmaceutical composition of claim 1 .

30 . A method of treating a lysosomal storage disorder, infection, metabolic disease, muscle disease, neurodegenerative disease, renal disease, hematologic disease, or optical disease, comprising administering to a subject an effective amount of the pharmaceutical composition of claim 1 .